SCHEMBL19998979

SCHEMBL19998979

Cc1cc(C(N)=O)nc2c1CCCC2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.56
NOS1 P29475 1/20 0.56
NOS2 P35228 1/20 0.56
KDM4E B2RXH2 2/20 0.44
EEF2K O00418 3/20 0.43
ACHE P22303 5/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
PRNP P04156 1/20 0.39
PPARG P37231 1/20 0.39
HTT P42858 1/20 0.39
NCOA2 Q15596 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RXFP1 Q9HBX9 1/20 0.39
NR2E3 Q9Y5X4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18320768 0.80 KDM4E (0.40) NOS3NOS1NOS2KDM4EEEF2K
SCHEMBL19658235 0.78 LMNA (0.47) KDM4EEEF2KACHELMNAPOLB
SCHEMBL3120976 0.78 KDM4E (0.41) NOS3NOS1NOS2KDM4EEEF2K
SCHEMBL30970534 0.78 KDM4E (0.44) NOS3NOS1NOS2KDM4EEEF2K
SCHEMBL18320808 0.77 POLB (0.40) KDM4EACHELMNAPOLBL3MBTL1
SCHEMBL4928326 0.72 NOS3 (0.60) NOS3NOS1NOS2KDM4EACHE
SCHEMBL11942291 0.72 LMNA (0.47) LMNASMN1; SMN2POLBHTT
SCHEMBL8330175 0.72 NOS3 (1.00) NOS3NOS1NOS2KDM4EACHE
SCHEMBL23181388 0.71 GRM2 (0.71)
SCHEMBL21260230 0.71 GRM2 (0.40) NOS3NOS1NOS2KDM4EEEF2K

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180085358-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE MERCK SHARP & DOHME CORP. (US) 2018-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180085358-A1 CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE GRM2, GRIN2A, GRIA2 NOS3 3064/4885NOS1 2707/4885NOS2 1603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.